Fusion proteins for the treatment of cns
AssigneeAcorda Therapeutics, Inc.
InventorsElliott A. GRUSKIN, Anthony O. CAGGIANO, Gargi ROY, Jennifer IACI, Michael P. ZIMBER
Life of this patent
Estimating the term…
Abstract
This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.
Claims21
1-45. (canceled)
A composition comprising:
- a polypeptide comprising a protein transduction domain and a proteoglycan degrading domain, wherein the proteoglycan degrading domain is selected from the group consisting of chondroitinase ABC I (SEQ ID NO:
- 50), chondroitinase ABC II (SEQ ID NO:
- 35), hyaluronidase-1 (SEQ ID NO:
- 38), hyaluronidase-2 (SEQ ID NO:
- 39), hyaluronidase-3 (SEQ ID NO:
- 40), hyaluronidase-4 (SEQ ID NO:
- 41), PH-20 (SEQ ID NO:
- 42), chondroitinase B (SEQ ID NO:
- 37), chondroitinase AC (SEQ ID NO:
- 36), and a combination thereof.
A method of promoting recovery of neurological function comprising:
- administering to a subject in need thereof a composition comprising a polypeptide comprising a protein transduction domain and a proteoglycan degrading domain, wherein the proteoglycan degrading domain is selected from the group consisting of chondroitinase ABC I (SEQ ID NO:
- 50), chondroitinase ABC II (SEQ ID NO:
- 35), hyaluronidase-1 (SEQ ID NO:
- 38), hyaluronidase-2 (SEQ ID NO:
- 39), hyaluronidase-3 (SEQ ID NO:
- 40), hyaluronidase-4 (SEQ ID NO:
- 41), PH-20 (SEQ ID NO:
- 42), chondroitinase B (SEQ ID NO:
- 37), chondroitinase AC (SEQ ID NO:
- 36), and a combination thereof.
Dependencies are inferred from the claim text.